UA106591C2 - Способ лечения гепатита с с применением интерферона и интерлейкина-1 - Google Patents

Способ лечения гепатита с с применением интерферона и интерлейкина-1

Info

Publication number
UA106591C2
UA106591C2 UAA201102255A UAA201102255A UA106591C2 UA 106591 C2 UA106591 C2 UA 106591C2 UA A201102255 A UAA201102255 A UA A201102255A UA A201102255 A UAA201102255 A UA A201102255A UA 106591 C2 UA106591 C2 UA 106591C2
Authority
UA
Ukraine
Prior art keywords
interleukin
pharmaceutical formulation
insulin
interferon
hepatitis
Prior art date
Application number
UAA201102255A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ігор Анатолієвіч Помиткін
Тамара Алєксандровна Віткалова
Original Assignee
Тамара Алєксандровна Віткалова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тамара Алєксандровна Віткалова filed Critical Тамара Алєксандровна Віткалова
Publication of UA106591C2 publication Critical patent/UA106591C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу лечения гепатита С и заключается в введении лицу, нуждающемуся в этом, первой лекарственной формы, включающей интерферон в дозе 1x106-3х106 МЕ, и подкожном введении второй лекарственной формы, включающей интерлейкин-1 в дозе 0,01-1000 мкг.
UAA201102255A 2008-07-23 2008-07-23 Способ лечения гепатита с с применением интерферона и интерлейкина-1 UA106591C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/059643 WO2010009762A1 (en) 2008-07-23 2008-07-23 Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection

Publications (1)

Publication Number Publication Date
UA106591C2 true UA106591C2 (ru) 2014-09-25

Family

ID=40996585

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201102255A UA106591C2 (ru) 2008-07-23 2008-07-23 Способ лечения гепатита с с применением интерферона и интерлейкина-1

Country Status (3)

Country Link
EA (1) EA022952B1 (ru)
UA (1) UA106591C2 (ru)
WO (1) WO2010009762A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2468815C1 (ru) * 2011-08-08 2012-12-10 Федеральное государственное бюджетное учреждение "Научный центр здоровья детей" Российской академии медицинских наук Способ повышения эффективности интерферонотерапии хронического гепатита с у детей
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
WO2017053990A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
WO2022133494A1 (en) * 2020-12-17 2022-06-23 The Regents Of The University Of California Antiviral compounds and applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP1446142A1 (en) * 2001-09-27 2004-08-18 Igor Anatolievich Pomytkin Potentiating the therapeutic effects of interferons
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Also Published As

Publication number Publication date
EA022952B1 (ru) 2016-03-31
EA201100322A8 (ru) 2013-06-28
EA201100322A1 (ru) 2011-10-31
WO2010009762A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
Patton et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells.
UA106591C2 (ru) Способ лечения гепатита с с применением интерферона и интерлейкина-1
JP2004525957A5 (ru)
Aman et al. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
Zhang et al. Cytokines and pulmonary fibrosis
Jeong et al. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity
McGee et al. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines
Kimura et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6
Rückerl et al. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1
Talmadge The pharmaceutics and delivery of therapeutic polypeptides and proteins
Ramos et al. Chlorella vulgaris modulates immunomyelopoietic activity and enhances the resistance of tumor-bearing mice
Pinkerton et al. Cultured human periodontal ligament cells constitutively express multiple osteotropic cytokines and growth factors, several of which are responsive to mechanical deformation
Hamblin Lymphokines and interleukins
Gorny et al. IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro
WO2006134195A8 (es) Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa
ATE447584T1 (de) Verfahren zur gewinnung von biologisch aktivem humanen g-csf aus inclusion bodies
Fantuzzi et al. IFN-α and IL-18 exert opposite regulatory effects on the IL-12 receptor expression and IL-12-induced IFN-γ production in mouse macrophages: novel pathways in the regulation of the inflammatory response of macrophages
Kukita et al. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells
Murohashi et al. Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in acute myeloblastic leukemia
WO2005123113A3 (en) Interferon compositions and methods of use thereof
Mundy et al. Cytokines of bone
Zdravkovic et al. Physiology and pathology of cytokine: Commercial production and medical use
WO2020231855A4 (en) Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
Ryff et al. Interferons and interleukins
Tilg et al. Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?